T2529

Zanamivir (GG167) is a guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.

DAT1 is an antimitotic and antiangiogenic that acts by binding to the colchicine binding site of tubulin.

Daunosamnyl-daunorubicin is used as an antibody conjugate.

DCCCyb is an orally bioavailable and selective GlyT1 Inhibitor. DCCCyb demonstrated excellent in vivo occupancy of GlyT1 transporters in rhesus monkeys as determined by the displacement of a PET tracer ligand.

DCFBC is a low-molecular-weight radiotracer. It targets prostate-specific membrane antigen (PSMA).

DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope F 18 with potential prostate tumor imaging upon positron emission tomogra

Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir (T2529) is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.